25 XP   0   0   10

BioCryst Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Biocryst together

I guess you are interested in BioCryst Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioCryst Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioCryst Pharmaceuticals Inc

I send you an email if I find something interesting about BioCryst Pharmaceuticals Inc.

Quick analysis of Biocryst (30 sec.)










What can you expect buying and holding a share of Biocryst? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.31
Expected worth in 1 year
$-3.02
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.72
Return On Investment
-11.2%

For what price can you sell your share?

Current Price per Share
$6.41
Expected price per share
$5.92 - $7.75
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Biocryst (5 min.)




Live pricePrice per Share (EOD)

$6.41

Intrinsic Value Per Share

$-7.88 - $-1.90

Total Value Per Share

$-10.19 - $-4.21

2. Growth of Biocryst (5 min.)




Is Biocryst growing?

Current yearPrevious yearGrowGrow %
How rich?-$476.1m-$269.6m-$465.2m-63.3%

How much money is Biocryst making?

Current yearPrevious yearGrowGrow %
Making money-$52.1m-$56.5m$4.4m8.5%
Net Profit Margin-59.3%-78.3%--

How much money comes from the company's main activities?

3. Financial Health of Biocryst (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#962 / 966

Most Revenue
#79 / 966

Most Profit
#867 / 966

Most Efficient
#422 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Biocryst? (5 min.)

Welcome investor! Biocryst's management wants to use your money to grow the business. In return you get a share of Biocryst.

What can you expect buying and holding a share of Biocryst?

First you should know what it really means to hold a share of Biocryst. And how you can make/lose money.

Speculation

The Price per Share of Biocryst is $6.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biocryst.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biocryst, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.31. Based on the TTM, the Book Value Change Per Share is $-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biocryst.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-2.7%-0.25-3.9%-0.27-4.3%-0.23-3.6%-0.16-2.4%
Usd Book Value Change Per Share-0.10-1.6%-0.18-2.8%-0.20-3.1%-0.12-1.9%-0.06-0.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.10-1.6%-0.18-2.8%-0.20-3.1%-0.12-1.9%-0.06-0.9%
Usd Price Per Share5.08-6.30-10.75-8.32-8.04-
Price to Earnings Ratio-7.41--6.84--10.23--12.79--15.22-
Price-to-Total Gains Ratio-50.80--18.74--57.40--29.25--59.79-
Price to Book Ratio-2.20--2.39--8.56--9.17-36.54-
Price-to-Total Gains Ratio-50.80--18.74--57.40--29.25--59.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.41
Number of shares156
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.18-0.12
Usd Total Gains Per Share-0.18-0.12
Gains per Quarter (156 shares)-27.95-18.85
Gains per Year (156 shares)-111.78-75.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-112-1220-75-85
20-224-2340-151-160
30-335-3460-226-235
40-447-4580-302-310
50-559-5700-377-385
60-671-6820-452-460
70-782-7940-528-535
80-894-9060-603-610
90-1006-10180-679-685
100-1118-11300-754-760

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%7.0114.00.05.8%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.031.00.022.5%29.092.00.024.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0121.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.031.00.022.5%29.092.00.024.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Biocryst

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Fundamental data was last updated by Penke on 2024-06-17 15:24:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of BioCryst Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biocryst earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • A Net Profit Margin of -38.1% means that $-0.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is -38.1%. The company is making a huge loss. -2
  • The TTM is -59.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-38.1%TTM-59.3%+21.2%
TTM-59.3%YOY-78.3%+19.0%
TTM-59.3%5Y-520.7%+461.4%
5Y-520.7%10Y-484.4%-36.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.1%-168.0%+129.9%
TTM-59.3%-209.9%+150.6%
YOY-78.3%-242.3%+164.0%
5Y-520.7%-401.7%-119.0%
10Y-484.4%-532.2%+47.8%
1.1.2. Return on Assets

Shows how efficient Biocryst is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • -7.6% Return on Assets means that Biocryst generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is -7.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-7.1%-0.5%
TTM-7.1%YOY-10.7%+3.5%
TTM-7.1%5Y-15.7%+8.6%
5Y-15.7%10Y-14.1%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-11.9%+4.3%
TTM-7.1%-11.9%+4.8%
YOY-10.7%-11.3%+0.6%
5Y-15.7%-13.5%-2.2%
10Y-14.1%-14.9%+0.8%
1.1.3. Return on Equity

Shows how efficient Biocryst is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • 0.0% Return on Equity means Biocryst generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-61.3%+61.3%
5Y-61.3%10Y-64.6%+3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.7%+15.7%
YOY--14.3%+14.3%
5Y-61.3%-19.2%-42.1%
10Y-64.6%-19.7%-44.9%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of BioCryst Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biocryst is operating .

  • Measures how much profit Biocryst makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • An Operating Margin of -11.3% means the company generated $-0.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is -11.3%. The company is operating very inefficient. -2
  • The TTM is -23.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-11.3%TTM-23.9%+12.7%
TTM-23.9%YOY-43.9%+19.9%
TTM-23.9%5Y-462.3%+438.3%
5Y-462.3%10Y-436.0%-26.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.3%-354.6%+343.3%
TTM-23.9%-225.9%+202.0%
YOY-43.9%-252.2%+208.3%
5Y-462.3%-428.3%-34.0%
10Y-436.0%-531.1%+95.1%
1.2.2. Operating Ratio

Measures how efficient Biocryst is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.15 means that the operating costs are $1.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 1.155. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.250. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.155TTM1.250-0.095
TTM1.250YOY1.439-0.189
TTM1.2505Y5.756-4.506
5Y5.75610Y5.564+0.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1553.004-1.849
TTM1.2503.332-2.082
YOY1.4393.502-2.063
5Y5.7565.271+0.485
10Y5.5646.915-1.351
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of BioCryst Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biocryst is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.73 means the company has $3.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 3.728. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.961. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.728TTM3.961-0.233
TTM3.961YOY5.521-1.559
TTM3.9615Y3.432+0.529
5Y3.43210Y2.529+0.903
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7283.767-0.039
TTM3.9614.000-0.039
YOY5.5214.905+0.616
5Y3.4325.883-2.451
10Y2.5296.286-3.757
1.3.2. Quick Ratio

Measures if Biocryst is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • A Quick Ratio of 5.41 means the company can pay off $5.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 5.415. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.218. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.415TTM4.218+1.197
TTM4.218YOY7.163-2.945
TTM4.2185Y3.890+0.328
5Y3.89010Y3.101+0.789
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4153.054+2.361
TTM4.2183.506+0.712
YOY7.1634.756+2.407
5Y3.8905.757-1.867
10Y3.1016.338-3.237
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of BioCryst Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biocryst assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biocryst to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.02 means that Biocryst assets are financed with 201.8% credit (debt) and the remaining percentage (100% - 201.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 2.018. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.068. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ2.018TTM1.068+0.950
TTM1.068YOY1.508-0.440
TTM1.0685Y1.190-0.122
5Y1.19010Y0.912+0.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0180.330+1.688
TTM1.0680.342+0.726
YOY1.5080.287+1.221
5Y1.1900.368+0.822
10Y0.9120.382+0.530
1.4.2. Debt to Equity Ratio

Measures if Biocryst is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biocryst to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioCryst Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.303-2.303
5Y2.30310Y3.969-1.665
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.365-0.365
TTM-0.415-0.415
YOY-0.370-0.370
5Y2.3030.443+1.860
10Y3.9690.476+3.493
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of BioCryst Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biocryst generates.

  • Above 15 is considered overpriced but always compare Biocryst to the Biotechnology industry mean.
  • A PE ratio of -7.41 means the investor is paying $-7.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioCryst Pharmaceuticals Inc:

  • The EOD is -9.348. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.408. Based on the earnings, the company is expensive. -2
  • The TTM is -6.835. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.348MRQ-7.408-1.940
MRQ-7.408TTM-6.835-0.573
TTM-6.835YOY-10.228+3.392
TTM-6.8355Y-12.787+5.951
5Y-12.78710Y-15.221+2.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.348-2.341-7.007
MRQ-7.408-2.997-4.411
TTM-6.835-2.882-3.953
YOY-10.228-3.553-6.675
5Y-12.787-6.262-6.525
10Y-15.221-6.288-8.933
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioCryst Pharmaceuticals Inc:

  • The EOD is -6.134. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.861. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -18.455. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.134MRQ-4.861-1.273
MRQ-4.861TTM-18.455+13.594
TTM-18.455YOY-18.188-0.267
TTM-18.4555Y-15.267-3.188
5Y-15.26710Y-36.037+20.771
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.134-2.932-3.202
MRQ-4.861-3.739-1.122
TTM-18.455-3.776-14.679
YOY-18.188-4.917-13.271
5Y-15.267-7.942-7.325
10Y-36.037-8.503-27.534
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biocryst is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -2.20 means the investor is paying $-2.20 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioCryst Pharmaceuticals Inc:

  • The EOD is -2.778. Based on the equity, the company is expensive. -2
  • The MRQ is -2.202. Based on the equity, the company is expensive. -2
  • The TTM is -2.389. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.778MRQ-2.202-0.576
MRQ-2.202TTM-2.389+0.187
TTM-2.389YOY-8.560+6.171
TTM-2.3895Y-9.171+6.782
5Y-9.17110Y36.540-45.710
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.7781.843-4.621
MRQ-2.2022.249-4.451
TTM-2.3892.301-4.690
YOY-8.5602.412-10.972
5Y-9.1713.782-12.953
10Y36.5404.212+32.328
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BioCryst Pharmaceuticals Inc.

3.1. Institutions holding BioCryst Pharmaceuticals Inc

Institutions are holding 90.027% of the shares of BioCryst Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31BlackRock Inc8.93550.002218440729-240641-1.2881
2024-03-31Vanguard Group Inc8.56530.001817676767-86953-0.4895
2024-03-31State Street Corporation8.46860.00417477344470034136.7875
2024-03-31venBio Select Advisor LLC6.32340.77321305000000
2024-03-31Baker Bros Advisors LP4.90660.64531012617600
2024-03-31Kynam Capital Management, LP3.16293.47056527491192749141.902
2024-03-31Deerfield Management Co2.42030.44154995000170900052.0085
2024-03-31Geode Capital Management, LLC2.13220.002144002711396333.2773
2024-03-31Alkeon Capital Management, LLC1.98640.035740994842430000145.554
2024-03-31RP Management, LLC1.863710.8463384615400
2024-03-31Rock Springs Capital Management LP1.69410.450934962562258756.9067
2024-03-31GW&K Investment Management, LLC1.67360.15473453908111622547.7492
2024-03-31BRAIDWELL LP1.63760.55333379577-1983403-36.9832
2024-03-31Fisher Asset Management, LLC1.39770.00682884619500.0017
2024-03-31Nuveen Asset Management, LLC1.26950.0042619861-847103-24.4336
2024-03-31Two Sigma Advisers, LLC1.19850.029124734122054009.0564
2024-03-31Ameriprise Financial Inc1.13150.00332335191112221292.517
2024-03-31Citigroup Inc1.10220.00762274775108081190.5229
2023-12-31NORGES BANK1.07410.00232216612106449692.3949
2024-03-31Rice Hall James & Associates, LLC1.04250.6242151545-45716-2.0806
Total 61.986218.0586127925172+12517718+9.8%

3.2. Funds holding BioCryst Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-05-31SPDR® S&P Biotech ETF6.12711.227812644963-149109-1.1655
2024-04-30Vanguard Total Stock Mkt Idx Inv3.18650.001865761991358822.1099
2024-05-30iShares Russell 2000 ETF2.13090.04894397626334400.7662
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr1.53050.01333158681-625-0.0198
2024-04-30Vanguard Small Cap Index1.26190.00782604369-1545-0.0593
2024-03-31Fidelity Small Cap Index0.92380.03621906599-24232-1.255
2024-04-30Fidelity Select Biotechnology0.8660.1706178718100
2024-04-30Vanguard Small Cap Growth Index Inv0.71320.01811471854-7046-0.4764
2024-05-30iShares Biotechnology ETF0.69050.13271425029-5388-0.3767
2024-05-30Direxion Daily S&P Biotech Bull 3X ETF0.61830.7565127610000
2024-04-30Nuveen Quant Small Cap Equity R60.60230.16681242950157401.2826
2024-05-30iShares Russell 2000 Growth ETF0.58640.0727121025700
2024-05-31State St Russell Sm/Mid Cp® Indx NL Cl C0.56480.0179116570000
2024-04-30Fidelity Extended Market Index0.56460.01321165119-10558-0.898
2024-05-31Schwab US Small-Cap ETF™0.47620.0388982781134761.3903
2024-04-30CREF Stock R10.43220.003189202042422090.6841
2024-03-31Vanguard Explorer Inv0.43210.019889179400
2024-03-31Columbia Small Cap Value II0.35770.30257381097381090
2024-03-31Columbia Small Cap Value I0.34810.24527183119503615.2478
2024-04-30Vanguard Russell 2000 ETF0.34590.030971376282841.1742
Total 22.7593.324646969404+1265684+2.7%

3.3. Insider Transactions

Insiders are holding 1.131% of the shares of BioCryst Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-05-30Alan G LevinBUY78616.36
2024-05-24Steve AselageBUY25006.4
2024-05-20Nancy J HutsonBUY50006.38
2024-05-14Anthony DoyleBUY363005.57
2024-05-14Helen M ThackrayBUY300005.86
2024-05-13Steven K GalsonBUY219405.49
2023-06-15Machelle SandersSELL40007.98
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BioCryst Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.100-0.179+79%-0.199+99%-0.121+21%-0.057-43%
Book Value Per Share---2.307-3.561+54%-1.307-43%-1.099-52%-0.422-82%
Current Ratio--3.7283.961-6%5.521-32%3.432+9%2.529+47%
Debt To Asset Ratio--2.0181.068+89%1.508+34%1.190+70%0.912+121%
Debt To Equity Ratio----0%-0%2.303-100%3.969-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.171-0.253+47%-0.274+60%-0.231+35%-0.156-9%
Free Cash Flow Per Share---0.261-0.125-52%-0.161-38%-0.160-39%-0.112-57%
Free Cash Flow To Equity Per Share---0.266-0.094-65%-0.057-79%0.049-646%0.036-845%
Gross Profit Margin--1.0001.069-6%1.048-5%1.045-4%1.022-2%
Intrinsic Value_10Y_max---1.900--------
Intrinsic Value_10Y_min---7.878--------
Intrinsic Value_1Y_max---0.410--------
Intrinsic Value_1Y_min---0.672--------
Intrinsic Value_3Y_max---1.065--------
Intrinsic Value_3Y_min---2.132--------
Intrinsic Value_5Y_max---1.518--------
Intrinsic Value_5Y_min---3.707--------
Market Cap1322876518.720+21%1048395119.3601299659107.120-19%2218552664.000-53%1717108167.688-39%1659451595.548-37%
Net Profit Margin---0.381-0.593+55%-0.783+105%-5.207+1265%-4.844+1170%
Operating Margin---0.113-0.239+112%-0.439+289%-4.623+4001%-4.360+3768%
Operating Ratio--1.1551.250-8%1.439-20%5.756-80%5.564-79%
Pb Ratio-2.778-26%-2.202-2.389+8%-8.560+289%-9.171+317%36.540-106%
Pe Ratio-9.348-26%-7.408-6.835-8%-10.228+38%-12.787+73%-15.221+105%
Price Per Share6.410+21%5.0806.298-19%10.750-53%8.320-39%8.041-37%
Price To Free Cash Flow Ratio-6.134-26%-4.861-18.455+280%-18.188+274%-15.267+214%-36.037+641%
Price To Total Gains Ratio-64.096-26%-50.797-18.742-63%-57.404+13%-29.253-42%-59.787+18%
Quick Ratio--5.4154.218+28%7.163-24%3.890+39%3.101+75%
Return On Assets---0.076-0.071-6%-0.107+41%-0.157+107%-0.141+87%
Return On Equity----0%-0%-0.6130%-0.6460%
Total Gains Per Share---0.100-0.179+79%-0.199+99%-0.121+21%-0.057-43%
Usd Book Value---476167000.000-734959000.000+54%-269693750.000-43%-226779150.000-52%-87189050.000-82%
Usd Book Value Change Per Share---0.100-0.179+79%-0.199+99%-0.121+21%-0.057-43%
Usd Book Value Per Share---2.307-3.561+54%-1.307-43%-1.099-52%-0.422-82%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.171-0.253+47%-0.274+60%-0.231+35%-0.156-9%
Usd Free Cash Flow---53919000.000-25889000.000-52%-33166750.000-38%-32976850.000-39%-23059925.000-57%
Usd Free Cash Flow Per Share---0.261-0.125-52%-0.161-38%-0.160-39%-0.112-57%
Usd Free Cash Flow To Equity Per Share---0.266-0.094-65%-0.057-79%0.049-646%0.036-845%
Usd Market Cap1322876518.720+21%1048395119.3601299659107.120-19%2218552664.000-53%1717108167.688-39%1659451595.548-37%
Usd Price Per Share6.410+21%5.0806.298-19%10.750-53%8.320-39%8.041-37%
Usd Profit---35379000.000-52146250.000+47%-56563500.000+60%-47687700.000+35%-32126425.000-9%
Usd Revenue--92761000.00088848750.000+4%72420500.000+28%45646500.000+103%26235400.000+254%
Usd Total Gains Per Share---0.100-0.179+79%-0.199+99%-0.121+21%-0.057-43%
 EOD+6 -2MRQTTM+17 -15YOY+14 -185Y+16 -1710Y+11 -22

4.2. Fundamental Score

Let's check the fundamental score of BioCryst Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.348
Price to Book Ratio (EOD)Between0-1-2.778
Net Profit Margin (MRQ)Greater than0-0.381
Operating Margin (MRQ)Greater than0-0.113
Quick Ratio (MRQ)Greater than15.415
Current Ratio (MRQ)Greater than13.728
Debt to Asset Ratio (MRQ)Less than12.018
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.076
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of BioCryst Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.174
Ma 20Greater thanMa 506.325
Ma 50Greater thanMa 1005.845
Ma 100Greater thanMa 2005.519
OpenGreater thanClose6.630
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets467,892
Total Liabilities944,059
Total Stockholder Equity-476,167
 As reported
Total Liabilities 944,059
Total Stockholder Equity+ -476,167
Total Assets = 467,892

Assets

Total Assets467,892
Total Current Assets447,100
Long-term Assets20,792
Total Current Assets
Cash And Cash Equivalents 84,333
Short-term Investments 252,221
Net Receivables 60,586
Inventory 29,781
Other Current Assets 18,381
Total Current Assets  (as reported)447,100
Total Current Assets  (calculated)445,302
+/- 1,798
Long-term Assets
Property Plant Equipment 7,831
Long-term Assets Other 12,961
Long-term Assets  (as reported)20,792
Long-term Assets  (calculated)20,792
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities119,921
Long-term Liabilities824,138
Total Stockholder Equity-476,167
Total Current Liabilities
Short-term Debt 2,740
Accounts payable 11,910
Other Current Liabilities 26,022
Total Current Liabilities  (as reported)119,921
Total Current Liabilities  (calculated)40,672
+/- 79,249
Long-term Liabilities
Long term Debt 813,036
Capital Lease Obligations Min Short Term Debt11,102
Long-term Liabilities  (as reported)824,138
Long-term Liabilities  (calculated)824,138
+/-0
Total Stockholder Equity
Common Stock2,063
Retained Earnings -1,716,538
Accumulated Other Comprehensive Income 771
Other Stockholders Equity 1,237,537
Total Stockholder Equity (as reported)-476,167
Total Stockholder Equity (calculated)-476,167
+/-0
Other
Capital Stock2,063
Cash and Short Term Investments 336,554
Common Stock Shares Outstanding 206,064
Current Deferred Revenue79,249
Liabilities and Stockholders Equity 467,892
Net Debt 742,545
Net Invested Capital 336,869
Net Working Capital 327,179
Short Long Term Debt Total 826,878



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-31
> Total Assets 
17,100
15,000
14,700
12,800
9,700
16,900
14,800
13,100
19,100
13,100
35,400
37,100
34,200
32,300
29,700
26,500
24,500
21,300
24,500
29,100
26,700
26,500
26,400
73,400
75,829
74,378
72,375
70,826
68,069
65,545
62,847
59,096
53,171
47,877
44,092
41,300
38,563
35,740
32,239
30,096
45,953
41,765
37,885
32,469
49,489
43,425
38,153
99,248
102,224
91,879
80,198
68,485
67,916
78,426
141,154
142,717
129,144
107,649
99,351
84,692
72,602
64,694
60,588
142,190
124,655
116,103
111,354
109,447
122,766
108,412
92,511
82,208
80,085
76,236
64,094
57,439
46,899
39,916
53,205
48,866
43,387
141,975
137,125
136,874
129,867
150,181
138,956
124,555
102,881
82,217
91,502
89,847
129,513
113,509
191,492
178,259
155,372
136,644
168,308
146,841
142,338
116,344
90,500
175,282
136,589
214,706
176,226
334,715
284,431
277,284
265,763
588,151
527,720
510,538
558,594
550,000
509,737
529,885
-685,518
516,960
467,892
467,892516,960-685,518529,885509,737550,000558,594510,538527,720588,151265,763277,284284,431334,715176,226214,706136,589175,28290,500116,344142,338146,841168,308136,644155,372178,259191,492113,509129,51389,84791,50282,217102,881124,555138,956150,181129,867136,874137,125141,97543,38748,86653,20539,91646,89957,43964,09476,23680,08582,20892,511108,412122,766109,447111,354116,103124,655142,19060,58864,69472,60284,69299,351107,649129,144142,717141,15478,42667,91668,48580,19891,879102,22499,24838,15343,42549,48932,46937,88541,76545,95330,09632,23935,74038,56341,30044,09247,87753,17159,09662,84765,54568,06970,82672,37574,37875,82973,40026,40026,50026,70029,10024,50021,30024,50026,50029,70032,30034,20037,10035,40013,10019,10013,10014,80016,9009,70012,80014,70015,00017,100
   > Total Current Assets 
12,700
13,200
13,000
11,100
8,100
15,400
13,400
11,700
17,800
11,700
34,200
28,100
23,500
28,200
25,100
19,700
20,500
19,600
22,900
22,900
19,400
18,200
20,000
24,600
27,396
27,148
26,450
25,760
34,084
33,101
31,627
32,404
29,975
27,731
27,882
24,931
23,557
26,076
20,174
20,704
29,088
24,705
23,524
23,872
41,708
33,791
31,479
81,100
71,794
61,246
48,659
45,790
47,288
51,428
91,561
91,705
77,259
55,620
80,111
75,025
65,129
57,451
50,686
111,022
92,790
79,755
89,762
87,419
100,451
79,877
72,674
52,858
52,949
58,547
46,582
41,978
35,407
33,530
46,839
42,121
35,731
138,250
135,144
89,343
81,366
107,088
84,502
65,990
50,425
46,112
64,632
66,987
113,502
92,263
175,370
125,391
104,156
92,669
128,495
114,352
117,649
103,719
78,803
164,345
125,508
203,837
162,436
323,800
273,771
265,802
252,743
566,136
511,714
494,853
509,001
516,500
490,883
414,115
397,590
495,966
447,100
447,100495,966397,590414,115490,883516,500509,001494,853511,714566,136252,743265,802273,771323,800162,436203,837125,508164,34578,803103,719117,649114,352128,49592,669104,156125,391175,37092,263113,50266,98764,63246,11250,42565,99084,502107,08881,36689,343135,144138,25035,73142,12146,83933,53035,40741,97846,58258,54752,94952,85872,67479,877100,45187,41989,76279,75592,790111,02250,68657,45165,12975,02580,11155,62077,25991,70591,56151,42847,28845,79048,65961,24671,79481,10031,47933,79141,70823,87223,52424,70529,08820,70420,17426,07623,55724,93127,88227,73129,97532,40431,62733,10134,08425,76026,45027,14827,39624,60020,00018,20019,40022,90022,90019,60020,50019,70025,10028,20023,50028,10034,20011,70017,80011,70013,40015,4008,10011,10013,00013,20012,700
       Cash And Cash Equivalents 
6,700
3,200
4,700
2,700
1,800
14,500
13,000
6,100
9,600
6,100
6,500
3,600
3,400
4,700
5,600
3,800
3,500
3,700
4,900
12,300
8,200
5,300
6,200
8,600
9,786
9,070
8,774
8,456
16,610
17,964
19,403
18,865
18,636
14,831
13,537
13,824
11,631
13,953
10,829
11,941
21,059
17,046
13,809
8,838
22,049
9,240
9,097
29,157
43,015
25,055
7,733
4,418
9,207
7,178
44,092
31,155
27,875
25,141
15,952
22,342
16,305
13,810
18,226
41,125
19,876
14,021
11,174
13,622
31,342
17,008
22,441
16,444
27,661
21,924
23,959
20,891
14,805
19,767
26,050
21,164
13,584
121,519
121,157
54,540
48,367
76,781
46,627
28,899
12,902
8,661
35,387
22,104
75,158
39,696
117,776
50,282
43,767
27,104
52,584
26,731
34,804
30,760
29,903
114,172
101,873
173,468
96,492
272,127
226,902
210,314
199,597
504,389
395,504
272,571
246,899
304,767
155,136
146,215
150,905
112,447
84,333
84,333112,447150,905146,215155,136304,767246,899272,571395,504504,389199,597210,314226,902272,12796,492173,468101,873114,17229,90330,76034,80426,73152,58427,10443,76750,282117,77639,69675,15822,10435,3878,66112,90228,89946,62776,78148,36754,540121,157121,51913,58421,16426,05019,76714,80520,89123,95921,92427,66116,44422,44117,00831,34213,62211,17414,02119,87641,12518,22613,81016,30522,34215,95225,14127,87531,15544,0927,1789,2074,4187,73325,05543,01529,1579,0979,24022,0498,83813,80917,04621,05911,94110,82913,95311,63113,82413,53714,83118,63618,86519,40317,96416,6108,4568,7749,0709,7868,6006,2005,3008,20012,3004,9003,7003,5003,8005,6004,7003,4003,6006,5006,1009,6006,10013,00014,5001,8002,7004,7003,2006,700
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,200
12,900
14,500
16,904
17,364
16,841
16,180
16,653
14,122
11,606
13,122
10,621
12,049
13,628
10,625
11,225
11,146
8,619
8,087
7,462
7,118
9,144
14,335
18,988
23,812
21,738
21,104
25,422
29,712
36,082
33,040
27,849
23,690
24,620
19,542
17,674
13,260
48,726
39,186
37,909
28,446
17,259
27,839
43,169
41,531
49,595
40,323
37,129
40,583
21,558
25,274
15,617
12,958
17,062
14,708
13,462
9,358
16,541
16,891
17,807
10,589
5,977
18,232
19,160
17,584
23,700
22,664
22,914
27,079
17,434
32,546
23,524
40,977
43,848
64,115
47,540
53,636
67,737
77,736
72,753
61,387
38,532
22,054
11,185
15,935
46,827
28,239
13,454
8,114
0
3,212
47,964
144,912
179,959
119,543
243,022
267,900
246,685
278,344
252,221
252,221278,344246,685267,900243,022119,543179,959144,91247,9643,21208,11413,45428,23946,82715,93511,18522,05438,53261,38772,75377,73667,73753,63647,54064,11543,84840,97723,52432,54617,43427,07922,91422,66423,70017,58419,16018,2325,97710,58917,80716,89116,5419,35813,46214,70817,06212,95815,61725,27421,55840,58337,12940,32349,59541,53143,16927,83917,25928,44637,90939,18648,72613,26017,67419,54224,62023,69027,84933,04036,08229,71225,42221,10421,73823,81218,98814,3359,1447,1187,4628,0878,61911,14611,22510,62513,62812,04910,62113,12211,60614,12216,65316,18016,84117,36416,90414,50012,90012,200000000000000000000000
       Net Receivables 
400
200
100
0
0
0
0
0
0
0
18,800
0
0
0
0
0
0
0
6,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
630
1,975
3,139
4,556
8,367
18,273
20,748
39,128
28,579
14,850
13,102
11,982
9,847
8,075
11,626
33,722
26,627
20,531
25,564
30,227
26,062
15,961
11,634
7,573
5,852
5,084
3,768
4,562
4,325
1,024
2,369
2,115
3,280
897
3,238
9,490
5,594
4,296
7,495
6,243
7,384
2,234
5,968
8,768
9,564
3,325
8,985
6,117
5,694
2,342
3,394
4,293
5,002
3,602
3,598
22,146
5,642
3,997
5,422
8,646
18,386
27,620
26,212
29,413
36,415
41,491
42,610
50,599
48,639
-364,841
-351,561
56,950
60,586
60,58656,950-351,561-364,84148,63950,59942,61041,49136,41529,41326,21227,62018,3868,6465,4223,9975,64222,1463,5983,6025,0024,2933,3942,3425,6946,1178,9853,3259,5648,7685,9682,2347,3846,2437,4954,2965,5949,4903,2388973,2802,1152,3691,0244,3254,5623,7685,0845,8527,57311,63415,96126,06230,22725,56420,53126,62733,72211,6268,0759,84711,98213,10214,85028,57939,12820,74818,2738,3674,5563,1391,97563030,00000000000000000000000000000006,000000000018,8000000000100200400
       Other Current Assets 
5,600
9,800
8,200
8,400
6,300
900
400
0
8,200
5,600
8,900
24,500
20,100
23,500
19,500
15,900
17,000
15,900
12,000
10,600
11,200
700
900
1,500
706
714
835
1,124
821
195
618
417
718
851
717
483
701
977
726
676
567
541
571
699
671
739
644
840
2,727
4,504
1,705
3,776
1,865
2,287
2,101
1,879
3,131
2,369
2,331
1,514
1,068
7,120
3,575
2,055
2,274
2,765
2,531
2,348
3,000
3,000
61,040
3,304
1,742
51,233
1,530
1,097
1,781
1,179
1,656
1,725
835
5,020
4,546
6,172
4,322
5,449
4,970
4,870
3,221
1,674
2,007
1,438
1,721
1,524
1,421
1,381
2,397
1,729
2,445
2,390
2,087
2,341
3,447
4,422
5,249
3,016
5,241
5,528
5,908
5,560
8,975
9,986
12,333
11,053
11,070
12,586
308,281
337,808
321,931
19,542
18,381
18,38119,542321,931337,808308,28112,58611,07011,05312,3339,9868,9755,5605,9085,5285,2413,0165,2494,4223,4472,3412,0872,3902,4451,7292,3971,3811,4211,5241,7211,4382,0071,6743,2214,8704,9705,4494,3226,1724,5465,0208351,7251,6561,1791,7811,0971,53051,2331,7423,30461,0403,0003,0002,3482,5312,7652,2742,0553,5757,1201,0681,5142,3312,3693,1311,8792,1012,2871,8653,7761,7054,5042,7278406447396716995715415676767269777014837178517184176181958211,1248357147061,50090070011,20010,60012,00015,90017,00015,90019,50023,50020,10024,5008,9005,6008,20004009006,3008,4008,2009,8005,600
   > Long-term Assets 
4,400
1,800
1,700
1,700
1,600
1,500
1,400
0
1,300
1,400
1,200
9,000
10,700
4,100
4,600
6,800
4,000
1,700
1,600
6,200
7,300
8,300
6,400
48,800
48,433
47,230
45,925
45,066
33,985
32,444
31,220
26,693
23,196
20,146
16,210
16,369
15,006
9,664
12,065
9,392
16,865
17,060
14,361
8,596
7,781
9,634
6,674
18,148
30,430
30,633
31,539
22,696
20,628
26,998
49,593
51,012
51,885
52,029
19,240
9,667
7,473
7,243
9,902
31,168
31,865
36,348
21,592
22,028
22,315
28,535
19,837
29,350
27,136
17,689
17,512
15,461
11,492
6,386
6,366
6,745
7,656
3,725
1,981
47,531
48,501
43,093
54,454
58,565
52,456
36,105
26,870
22,860
16,011
21,246
16,122
52,868
51,216
43,975
39,813
32,489
24,689
12,625
11,697
10,937
11,081
10,869
13,790
10,915
10,660
11,482
13,020
22,015
16,006
15,685
49,593
33,500
18,854
18,829
20,458
20,994
20,792
20,79220,99420,45818,82918,85433,50049,59315,68516,00622,01513,02011,48210,66010,91513,79010,86911,08110,93711,69712,62524,68932,48939,81343,97551,21652,86816,12221,24616,01122,86026,87036,10552,45658,56554,45443,09348,50147,5311,9813,7257,6566,7456,3666,38611,49215,46117,51217,68927,13629,35019,83728,53522,31522,02821,59236,34831,86531,1689,9027,2437,4739,66719,24052,02951,88551,01249,59326,99820,62822,69631,53930,63330,43018,1486,6749,6347,7818,59614,36117,06016,8659,39212,0659,66415,00616,36916,21020,14623,19626,69331,22032,44433,98545,06645,92547,23048,43348,8006,4008,3007,3006,2001,6001,7004,0006,8004,6004,10010,7009,0001,2001,4001,30001,4001,5001,6001,7001,7001,8004,400
       Property Plant Equipment 
1,900
1,800
1,700
1,700
1,600
1,500
1,400
1,400
1,300
1,400
1,200
1,100
1,300
1,700
1,700
1,600
1,600
1,600
1,500
1,400
1,500
1,500
1,600
1,800
1,875
2,177
2,823
3,837
4,213
4,069
4,916
5,396
5,349
5,177
4,867
4,557
4,277
3,987
3,737
3,508
3,387
3,163
2,948
2,817
2,634
2,456
2,342
2,408
2,760
2,671
2,679
3,029
3,062
3,169
4,120
5,294
5,086
5,232
5,271
4,880
4,566
4,429
4,175
3,872
3,564
3,330
3,087
1,929
1,734
1,537
1,353
1,098
999
882
751
583
486
425
359
306
260
216
210
207
727
1,047
1,146
5,149
8,362
10,112
10,095
9,922
9,753
9,602
9,613
9,546
9,395
9,390
9,236
9,135
7,644
7,551
7,452
7,347
7,270
7,149
7,142
7,113
10,660
11,482
13,020
8,714
16,006
15,685
15,261
15,423
8,376
8,438
8,999
20,994
7,831
7,83120,9948,9998,4388,37615,42315,26115,68516,0068,71413,02011,48210,6607,1137,1427,1497,2707,3477,4527,5517,6449,1359,2369,3909,3959,5469,6139,6029,7539,92210,09510,1128,3625,1491,1461,0477272072102162603063594254865837518829991,0981,3531,5371,7341,9293,0873,3303,5643,8724,1754,4294,5664,8805,2715,2325,0865,2944,1203,1693,0623,0292,6792,6712,7602,4082,3422,4562,6342,8172,9483,1633,3873,5083,7373,9874,2774,5574,8675,1775,3495,3964,9164,0694,2133,8372,8232,1771,8751,8001,6001,5001,5001,4001,5001,6001,6001,6001,7001,7001,3001,1001,2001,4001,3001,4001,4001,5001,6001,7001,7001,8001,900
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,984
16,416
15,382
13,067
16,351
2,513
1,151
0
0
680
2,582
2,679
602
302
41,116
41,116
36,059
0
47,683
41,134
0
0
8,926
0
0
4,539
41,295
41,599
33,744
29,157
22,376
11,655
741
0
0
0
0
3,002
0
0
0
0
6,829
0
0
34,332
18,077
3,432
3,445
0
0
0
0003,4453,43218,07734,332006,82900003,002000074111,65522,37629,15733,74441,59941,2954,539008,9260041,13447,683036,05941,11641,1163026022,6792,582680001,1512,51316,35113,06715,38216,41612,984000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
100
100
100
0
100
100
200
189
193
244
281
294
302
312
343
453
83
89
98
97
97
116
179
185
195
242
249
258
268
284
188
222
248
260
291
303
314
297
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000002973143032912602482221882842682582492421951851791169797988983453343312302294281244193189200100100010010010010010010000000000000000
       Long-term Assets Other 
2,500
0
0
0
0
0
0
0
0
100
0
7,900
9,400
2,400
2,800
5,100
2,300
0
0
4,700
5,800
6,700
4,700
46,800
46,369
44,860
42,858
40,948
29,478
28,073
25,992
20,954
17,394
14,886
11,254
11,714
10,632
5,580
8,328
5,705
13,293
13,702
11,171
5,530
4,889
6,910
4,048
15,553
27,448
27,714
28,600
19,376
17,263
23,515
45,176
11,718
10,799
10,797
10,969
2,786
2,907
2,814
2,720
2,626
2,533
8,037
7,857
8,328
13,428
14,014
2,068
12,870
13,070
456
14,248
13,727
11,006
5,961
5,327
3,857
4,717
2,907
1,469
6,208
6,658
5,987
5,521
5,733
2,960
1,839
2,404
4,012
2,455
2,041
1,970
2,027
222
841
1,420
978
5,390
4,333
4,245
3,590
3,811
3,720
3,646
3,802
3,802
0
0
6,472
7,207
-15,685
-49,593
-33,500
7,046
6,946
11,459
13,084
12,961
12,96113,08411,4596,9467,046-33,500-49,593-15,6857,2076,472003,8023,8023,6463,7203,8113,5904,2454,3335,3909781,4208412222,0271,9702,0412,4554,0122,4041,8392,9605,7335,5215,9876,6586,2081,4692,9074,7173,8575,3275,96111,00613,72714,24845613,07012,8702,06814,01413,4288,3287,8578,0372,5332,6262,7202,8142,9072,78610,96910,79710,79911,71845,17623,51517,26319,37628,60027,71427,44815,5534,0486,9104,8895,53011,17113,70213,2935,7058,3285,58010,63211,71411,25414,88617,39420,95425,99228,07329,47840,94842,85844,86046,36946,8004,7006,7005,8004,700002,3005,1002,8002,4009,4007,9000100000000002,500
> Total Liabilities 
2,500
2,300
1,700
1,600
1,400
1,600
1,300
1,800
1,600
1,800
1,600
1,700
1,700
1,800
1,600
1,200
1,700
1,500
1,800
1,400
1,300
1,300
1,500
2,000
1,606
1,823
1,232
9,345
7,916
4,398
1,100
2,283
1,835
1,665
1,234
1,173
1,187
1,585
1,431
1,649
2,525
2,358
3,568
3,134
2,983
2,561
3,747
40,808
49,004
47,486
50,176
47,330
53,923
69,083
75,545
77,812
74,921
65,226
64,343
38,265
34,085
33,409
37,043
55,924
39,128
32,495
37,005
43,944
68,597
69,146
66,469
67,402
56,935
60,577
54,310
57,893
49,739
48,963
49,795
49,992
49,110
51,886
53,671
61,239
65,496
74,092
74,911
76,831
75,083
68,830
87,509
88,269
90,983
89,433
90,860
94,492
93,318
90,460
95,435
97,606
119,831
125,537
131,753
137,030
132,941
138,199
142,589
353,977
359,419
383,359
412,807
695,137
691,935
723,770
801,253
844,597
838,024
918,598
933,910
972,488
944,059
944,059972,488933,910918,598838,024844,597801,253723,770691,935695,137412,807383,359359,419353,977142,589138,199132,941137,030131,753125,537119,83197,60695,43590,46093,31894,49290,86089,43390,98388,26987,50968,83075,08376,83174,91174,09265,49661,23953,67151,88649,11049,99249,79548,96349,73957,89354,31060,57756,93567,40266,46969,14668,59743,94437,00532,49539,12855,92437,04333,40934,08538,26564,34365,22674,92177,81275,54569,08353,92347,33050,17647,48649,00440,8083,7472,5612,9833,1343,5682,3582,5251,6491,4311,5851,1871,1731,2341,6651,8352,2831,1004,3987,9169,3451,2321,8231,6062,0001,5001,3001,3001,4001,8001,5001,7001,2001,6001,8001,7001,7001,6001,8001,6001,8001,3001,6001,4001,6001,7002,3002,500
   > Total Current Liabilities 
1,400
1,300
700
800
600
800
700
1,100
1,100
1,100
1,200
1,400
1,300
1,400
1,200
900
1,400
1,100
1,500
1,100
900
1,000
1,200
1,700
1,303
1,523
932
4,122
3,395
4,098
800
1,983
1,535
1,365
934
873
887
1,285
1,131
1,348
2,225
2,058
3,268
2,834
2,683
2,261
3,447
11,382
11,007
9,681
12,905
10,735
13,579
17,157
24,735
28,118
25,945
17,346
17,559
17,108
13,562
13,464
17,735
37,253
21,094
15,098
20,246
27,822
21,771
21,960
19,333
26,299
16,165
19,106
12,564
17,224
11,324
11,958
13,182
15,256
13,689
44,937
49,823
57,687
61,862
63,772
64,444
64,453
63,070
56,194
51,520
54,360
58,557
58,937
69,237
74,836
75,342
74,173
64,357
69,477
66,326
71,948
82,169
92,335
92,699
102,650
111,777
105,654
101,201
115,601
133,608
103,718
81,017
95,390
81,637
105,514
85,157
93,498
90,763
149,988
119,921
119,921149,98890,76393,49885,157105,51481,63795,39081,017103,718133,608115,601101,201105,654111,777102,65092,69992,33582,16971,94866,32669,47764,35774,17375,34274,83669,23758,93758,55754,36051,52056,19463,07064,45364,44463,77261,86257,68749,82344,93713,68915,25613,18211,95811,32417,22412,56419,10616,16526,29919,33321,96021,77127,82220,24615,09821,09437,25317,73513,46413,56217,10817,55917,34625,94528,11824,73517,15713,57910,73512,9059,68111,00711,3823,4472,2612,6832,8343,2682,0582,2251,3481,1311,2858878739341,3651,5351,9838004,0983,3954,1229321,5231,3031,7001,2001,0009001,1001,5001,1001,4009001,2001,4001,3001,4001,2001,1001,1001,1007008006008007001,3001,400
       Short-term Debt 
400
400
300
300
200
200
300
300
300
300
300
200
200
100
100
100
0
0
0
0
0
0
0
0
26
23
17
10
3
0
0
300,000
300
0
0
0
300
0
0
300,000
300
0
0
300,000
0
0
0
0
0
0
0
0
0
0
0
0
6,386
3,644
9,935
9,237
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
30,000
30,000
30,000
30,000
30,000
30,000
27,914
28,023
28,133
28,243
29,629
31,460
33,372
35,221
35,365
35,510
30,699
33,748
29,231
29,341
34,939
39,958
44,998
49,932
49,963
31,179
31,001
30,981
31,452
1,819
2,081
2,134
2,196
2,369
2,491
2,530
2,282
26,213
2,740
2,74026,2132,2822,5302,4912,3692,1962,1342,0811,81931,45230,98131,00131,17949,96349,93244,99839,95834,93929,34129,23133,74830,69935,51035,36535,22133,37231,46029,62928,24328,13328,02327,91430,00030,00030,00030,00030,00030,00030,0000000000000000000000009,2379,9353,6446,386000000000000300,00000300300,00000300000300300,0000031017232600000000100100100200200300300300300300200200300300400400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
0
0
0
27,804
0
0
0
28,243
1,276
54,163
33,299
35,146
35,289
35,432
30,633
33,701
29,231
29,341
33,487
38,581
43,697
48,836
49,038
30,000
30,000
30,000
30,000
0
0
0
0
0
0
0
0
0
0
000000000030,00030,00030,00030,00049,03848,83643,69738,58133,48729,34129,23133,70130,63335,43235,28935,14633,29954,1631,27628,24300027,80400030,00000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
700
700
400
300
200
400
300
0
400
400
600
600
700
700
600
200
700
300
500
200
200
300
100
300
405
915
254
804
240
292
367
618
350
775
460
256
271
617
459
640
1,054
849
2,024
1,970
1,672
1,208
2,231
8,813
6,867
5,206
7,974
5,887
8,209
10,578
16,383
19,771
14,763
9,317
3,239
5,266
4,185
2,793
3,200
18,070
6,352
1,438
3,261
8,201
6,254
5,012
3,583
2,497
2,062
3,328
2,293
3,974
1,073
989
1,241
4,174
1,352
2,360
2,266
2,849
5,307
3,822
3,782
9,307
7,691
5,051
2,760
4,269
5,433
1,844
4,603
6,337
3,588
4,122
7,911
7,769
6,935
8,298
10,084
13,988
10,061
9,354
11,616
18,713
13,529
10,087
19,693
27,808
13,881
12,024
8,622
14,356
6,254
13,889
10,567
20,893
11,910
11,91020,89310,56713,8896,25414,3568,62212,02413,88127,80819,69310,08713,52918,71311,6169,35410,06113,98810,0848,2986,9357,7697,9114,1223,5886,3374,6031,8445,4334,2692,7605,0517,6919,3073,7823,8225,3072,8492,2662,3601,3524,1741,2419891,0733,9742,2933,3282,0622,4973,5835,0126,2548,2013,2611,4386,35218,0703,2002,7934,1855,2663,2399,31714,76319,77116,38310,5788,2095,8877,9745,2066,8678,8132,2311,2081,6721,9702,0248491,0546404596172712564607753506183672922408042549154053001003002002005003007002006007007006006004004000300400200300400700700
       Other Current Liabilities 
300
200
0
200
200
200
100
0
400
400
300
600
400
600
500
600
700
800
1,000
900
700
700
1,100
1,400
290
485
661
-2,810,137
339
407
433
1,365
1,185
590
474
617
616
668
672
708
1,171
1,209
1,244
864
1,011
1,053
1,216
1,695
1,978
2,084
2,232
2,148
2,209
1,959
3,672
3,688
40
40
40
40
6,790
8,090
11,973
16,687
12,245
11,163
14,488
17,125
12,968
13,627
12,380
14,016
11,703
11,706
8,963
11,858
8,715
9,431
10,402
9,609
10,864
11,095
16,076
17,752
19,532
23,451
28,544
22,983
25,302
20,986
18,345
19,826
21,626
23,916
22,576
24,794
29,089
34,241
25,547
27,739
29,939
34,088
36,925
36,269
36,573
42,649
49,766
55,612
56,266
73,982
81,861
72,670
63,584
79,711
69,265
87,565
75,212
75,300
77,392
102,882
26,022
26,022102,88277,39275,30075,21287,56569,26579,71163,58472,67081,86173,98256,26655,61249,76642,64936,57336,26936,92534,08829,93927,73925,54734,24129,08924,79422,57623,91621,62619,82618,34520,98625,30222,98328,54423,45119,53217,75216,07611,09510,8649,60910,4029,4318,71511,8588,96311,70611,70314,01612,38013,62712,96817,12514,48811,16312,24516,68711,9738,0906,790404040403,6883,6721,9592,2092,1482,2322,0841,9781,6951,2161,0531,0118641,2441,2091,1717086726686166174745901,1851,365433407339-2,810,1376614852901,4001,1007007009001,00080070060050060040060030040040001002002002000200300
   > Long-term Liabilities 
1,100
1,000
1,000
800
800
800
600
0
500
700
400
300
400
400
400
300
300
400
300
300
400
300
300
300
303
300
300
5,224
4,521
300
300
300
300
300
300
300
300
300
300
301
300
300
300
300
300
300
300
29,426
37,997
37,805
37,271
36,596
40,344
51,926
50,810
49,694
48,976
47,880
46,784
21,157
20,523
19,945
19,308
18,671
18,034
17,397
16,759
16,122
46,826
47,186
66,469
41,103
40,770
60,577
41,746
40,669
38,415
37,005
36,613
34,736
35,421
6,949
3,848
3,552
3,634
10,320
10,467
12,378
12,013
12,636
35,989
33,909
32,426
30,496
21,623
19,656
17,976
16,287
31,078
28,129
53,505
53,589
49,584
44,695
40,242
35,549
30,812
248,323
258,218
267,758
279,199
591,419
610,918
628,380
719,616
739,083
5,934
5,803
9,966
822,500
824,138
824,138822,5009,9665,8035,934739,083719,616628,380610,918591,419279,199267,758258,218248,32330,81235,54940,24244,69549,58453,58953,50528,12931,07816,28717,97619,65621,62330,49632,42633,90935,98912,63612,01312,37810,46710,3203,6343,5523,8486,94935,42134,73636,61337,00538,41540,66941,74660,57740,77041,10366,46947,18646,82616,12216,75917,39718,03418,67119,30819,94520,52321,15746,78447,88048,97649,69450,81051,92640,34436,59637,27137,80537,99729,4263003003003003003003003013003003003003003003003003003004,5215,22430030030330030030040030030040030030040040040030040070050006008008008001,0001,0001,100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
0
0
0
30,000
30,000
30,000
0
0
0
0
0
0
0
0
0
0
0
0
28,075
49,616
49,847
46,041
41,289
36,513
0
0
119,735
123,039
126,796
132,050
136,082
140,236
144,516
223,867
0
232,522
293,176
0
0
0
000293,176232,5220223,867144,516140,236136,082132,050126,796123,039119,7350036,51341,28946,04149,84749,61628,07500000000000030,00030,00030,00000030,00030,00030,00030,00030,00030,00030,00030,00030,00030,00030,00030,000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
300
300
5,223
4,521
300
300
300
300
300
300
299
300
300
300
300
300
300
300
300
300
300
300
29,426
37,997
37,805
37,271
36,595
40,344
51,926
50,810
49,694
48,976
47,880
46,784
21,157
20,523
19,945
19,308
18,671
18,034
17,397
16,759
16,122
16,826
17,186
17,136
11,103
10,770
11,471
11,746
10,669
8,415
7,005
6,613
4,736
5,421
6,949
3,848
3,552
3,634
10,320
10,467
10,003
9,507
10,047
10,649
8,428
8,111
7,793
474
155
131
107
81
54
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000054811071311554747,7938,1118,42810,64910,0479,50710,00310,46710,3203,6343,5523,8486,9495,4214,7366,6137,0058,41510,66911,74611,47110,77011,10317,13617,18616,82616,12216,75917,39718,03418,67119,30819,94520,52321,15746,78447,88048,97649,69450,81051,92640,34436,59537,27137,80537,99729,4263003003003003003003003003003003002993003003003003003004,5215,223300300300000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,846
14,210
7,103
6,808
6,512
6,215
5,920
5,624
5,327
5,032
4,736
4,440
6,949
3,848
3,552
3,634
10,320
10,467
9,674
9,507
10,047
10,649
8,428
8,111
7,793
474
155
131
107
81
54
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000054811071311554747,7938,1118,42810,64910,0479,5079,67410,46710,3203,6343,5523,8486,9494,4404,7365,0325,3275,6245,9206,2156,5126,8087,10314,21014,846000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
14,600
12,700
13,000
11,200
8,300
15,300
13,500
0
17,500
11,300
33,800
35,400
32,500
30,500
28,100
25,300
22,800
19,800
22,700
27,700
25,400
25,200
24,900
71,400
74,223
72,555
71,143
61,481
60,153
61,147
61,747
56,814
51,336
46,212
42,858
40,128
37,376
34,155
30,808
28,447
43,428
39,407
34,317
29,334
46,506
40,864
34,406
58,440
53,220
44,393
30,022
21,155
13,993
9,343
65,609
64,905
54,223
42,423
35,008
46,426
38,517
31,285
23,545
86,266
85,527
83,608
74,349
65,503
54,169
39,266
26,042
14,806
23,150
15,659
9,784
-454
-2,840
-9,047
3,410
-1,126
-5,723
90,089
83,454
75,635
64,371
76,089
64,045
47,724
27,798
13,387
3,993
1,578
38,530
24,076
100,632
83,767
62,054
46,184
72,873
49,235
22,507
-9,193
-41,253
38,252
3,648
76,507
33,637
-19,262
-74,988
-106,075
-147,044
-106,986
-1,281,700
-1,340,559
-1,383,079
-1,454,621
-1,507,953
-1,583,279
-1,619,428
-455,528
-476,167
-476,167-455,528-1,619,428-1,583,279-1,507,953-1,454,621-1,383,079-1,340,559-1,281,700-106,986-147,044-106,075-74,988-19,26233,63776,5073,64838,252-41,253-9,19322,50749,23572,87346,18462,05483,767100,63224,07638,5301,5783,99313,38727,79847,72464,04576,08964,37175,63583,45490,089-5,723-1,1263,410-9,047-2,840-4549,78415,65923,15014,80626,04239,26654,16965,50374,34983,60885,52786,26623,54531,28538,51746,42635,00842,42354,22364,90565,6099,34313,99321,15530,02244,39353,22058,44034,40640,86446,50629,33434,31739,40743,42828,44730,80834,15537,37640,12842,85846,21251,33656,81461,74761,14760,15361,48171,14372,55574,22371,40024,90025,20025,40027,70022,70019,80022,80025,30028,10030,50032,50035,40033,80011,30017,500013,50015,3008,30011,20013,00012,70014,600
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
200
200
200
174
175
175
175
175
175
176
176
176
176
177
177
177
177
177
179
215
217
217
218
262
262
264
288
291
292
292
292
294
295
380
380
381
381
382
383
383
383
387
439
440
449
449
450
451
451
452
457
492
501
509
509
514
542
591
591
601
717
719
720
725
732
733
734
737
737
738
738
804
804
984
984
987
989
1,096
1,101
1,103
1,104
1,104
1,541
1,542
1,764
1,766
1,769
1,777
1,787
1,798
1,843
1,856
1,859
1,864
1,879
1,889
1,895
1,898
2,058
2,063
2,0632,0581,8981,8951,8891,8791,8641,8591,8561,8431,7981,7871,7771,7691,7661,7641,5421,5411,1041,1041,1031,1011,096989987984984804804738738737737734733732725720719717601591591542514509509501492457452451451450449449440439387383383383382381381380380295294292292292291288264262262218217217215179177177177177177176176176176175175175175175174200200200000000000000000000000
   Retained Earnings -1,716,538-1,681,159-1,619,428-1,583,279-1,507,953-1,454,621-1,383,079-1,340,559-1,281,700-1,207,504-1,189,725-1,130,924-1,087,726-1,023,442-962,949-916,834-878,227-840,628-838,006-800,414-762,785-731,969-704,537-674,940-656,494-631,843-612,300-597,166-580,280-566,061-561,558-550,030-533,749-510,917-492,782-478,161-483,062-467,898-456,226-447,495-432,846-422,709-417,280-409,279-397,107-392,601-381,548-371,848-359,572-353,520-340,328-325,870-309,599-296,572-286,372-275,508-265,315-262,719-277,871-267,244-258,560-249,268-259,338-250,343-237,634-224,536-222,253-211,269-204,306-195,481-185,431-169,828-159,745-151,863-144,702-137,057-131,409-125,764-120,475-115,179-110,121-104,660-101,410-98,001-94,748-91,960-89,224-85,809-80,647-75,031-70,053-70,470-71,428-70,045-60,247-58,604-56,609-58,500-58,000-55,800-55,600-53,200-51,700-54,400-51,400-48,400-45,500-43,000-40,900-37,800-35,700-30,100-32,000-30,100-27,900-26,000-24,400-21,500-19,600-18,000-16,100
   Accumulated Other Comprehensive Income 
-500
-500
-500
-1,600
-1,600
-1,600
-1,600
-1,700
-1,700
-1,700
-2,100
-1,900
-1,900
-2,200
-2,400
-1,600
-1,600
-1,600
-2,000
-1,800
-1,900
-2,000
-2,100
-1,900
-1,900
-2,220
-2,220
-2,564
-2,564
-2,564
-2,564
-3,610
-3,610
-3,610
-3,610
-4,857
-4,857
-4,857
-4,857
-5,958
-5,958
-5,958
-5,958
-6,913
-6,913
-6,913
-6,913
-7,708
-7,708
9
54
32
26
-4
152
378
726
252
133
104
68
40
40
-26
77
63
119
106
82
92
50
40
49
40
40
27
15
6
2
4
2
3
2
-130
10
-92
-1
-206
48
46
22
-12
-3
-15
-17
-243
-476
-452
-410
-297
-89
41
60
39
14
3
9
3
182
87
114
177
186
15
-98
26
585
690
800
1,337
771
7711,33780069058526-98151861771148718239314396041-89-297-410-452-476-243-17-15-3-12224648-206-1-9210-1302324261527404049405092821061196377-26404068104133252726378152-42632549-7,708-7,708-6,913-6,913-6,913-6,913-5,958-5,958-5,958-5,958-4,857-4,857-4,857-4,857-3,610-3,610-3,610-3,610-2,564-2,564-2,564-2,564-2,220-2,220-1,900-1,900-2,100-2,000-1,900-1,800-2,000-1,600-1,600-1,600-2,400-2,200-1,900-1,900-2,100-1,700-1,700-1,700-1,600-1,600-1,600-1,600-500-500-500
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
364,593
365,868
367,829
382,181
386,966
390,783
391,611
393,738
399,684
420,097
420,988
426,520
536,864
538,959
542,943
546,698
553,610
556,095
558,113
560,762
562,634
564,791
566,913
618,009
620,453
711,965
714,869
718,037
720,587
776,724
780,400
784,278
790,076
795,589
877,300
880,319
991,574
994,811
1,002,408
1,010,779
1,022,975
1,040,769
1,098,498
1,115,443
1,125,453
1,138,654
0
1,177,192
1,191,981
0
0
0
0001,191,9811,177,19201,138,6541,125,4531,115,4431,098,4981,040,7691,022,9751,010,7791,002,408994,811991,574880,319877,300795,589790,076784,278780,400776,724720,587718,037714,869711,965620,453618,009566,913564,791562,634560,762558,113556,095553,610546,698542,943538,959536,864426,520420,988420,097399,684393,738391,611390,783386,966382,181367,829365,868364,593000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
31,200
31,200
33,100
34,300
34,300
42,900
43,000
0
51,200
43,100
71,600
75,100
75,300
75,700
76,000
75,300
75,800
75,800
76,400
82,700
82,900
82,800
84,800
131,600
132,558
133,204
133,435
133,915
133,970
134,006
134,188
135,279
135,417
135,455
135,515
136,768
136,804
136,836
136,898
138,886
159,292
160,327
160,533
161,794
184,566
184,572
185,757
217,723
220,382
213,920
215,107
216,311
217,979
220,321
287,330
288,683
290,750
292,133
293,831
295,208
296,626
298,106
300,989
348,572
350,325
358,604
360,153
361,520
363,235
364,593
365,868
367,829
382,181
386,966
390,783
391,611
393,738
399,684
420,097
420,988
426,520
536,864
538,959
542,943
546,698
553,610
556,095
558,113
560,762
562,634
564,791
566,913
618,009
620,453
711,965
714,869
718,037
720,587
776,724
780,400
784,278
790,076
795,589
877,300
880,319
991,574
994,811
1,002,408
1,010,779
1,022,975
1,040,769
1,098,498
-2,042
-1,874
-1,766
-1,905
-2,474
-2,585
-2,698
1,222,236
1,237,537
1,237,5371,222,236-2,698-2,585-2,474-1,905-1,766-1,874-2,0421,098,4981,040,7691,022,9751,010,7791,002,408994,811991,574880,319877,300795,589790,076784,278780,400776,724720,587718,037714,869711,965620,453618,009566,913564,791562,634560,762558,113556,095553,610546,698542,943538,959536,864426,520420,988420,097399,684393,738391,611390,783386,966382,181367,829365,868364,593363,235361,520360,153358,604350,325348,572300,989298,106296,626295,208293,831292,133290,750288,683287,330220,321217,979216,311215,107213,920220,382217,723185,757184,572184,566161,794160,533160,327159,292138,886136,898136,836136,804136,768135,515135,455135,417135,279134,188134,006133,970133,915133,435133,204132,558131,60084,80082,80082,90082,70076,40075,80075,80075,30076,00075,70075,30075,10071,60043,10051,200043,00042,90034,30034,30033,10031,20031,200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue331,412
Cost of Revenue-6,316
Gross Profit325,096325,096
 
Operating Income (+$)
Gross Profit325,096
Operating Expense-428,805
Operating Income-103,709-103,709
 
Operating Expense (+$)
Research Development214,911
Selling General Administrative199,490
Selling And Marketing Expenses14,404
Operating Expense428,805428,805
 
Net Interest Income (+$)
Interest Income14,016
Interest Expense-108,239
Other Finance Cost-1,875
Net Interest Income-96,098
 
Pretax Income (+$)
Operating Income-103,709
Net Interest Income-96,098
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-226,22918,811
EBIT - interestExpense = -211,948
-226,229
-118,300
Interest Expense108,239
Earnings Before Interest and Taxes (EBIT)-103,709-117,990
Earnings Before Interest and Taxes (EBITDA)-102,054
 
After tax Income (+$)
Income Before Tax-226,229
Tax Provision-1,817
Net Income From Continuing Ops-236,349-228,046
Net Income-226,539
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses435,121
Total Other Income/Expenses Net-122,52096,098
 

Technical Analysis of Biocryst
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biocryst. The general trend of Biocryst is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biocryst's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioCryst Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.89 < 6.985 < 7.75.

The bearish price targets are: 6.04 > 5.97 > 5.92.

Tweet this
BioCryst Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioCryst Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioCryst Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioCryst Pharmaceuticals Inc. The current macd is 0.10600062.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biocryst price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Biocryst. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Biocryst price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioCryst Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioCryst Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioCryst Pharmaceuticals Inc. The current adx is 26.91.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biocryst shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
BioCryst Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioCryst Pharmaceuticals Inc. The current sar is 5.971552.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
BioCryst Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioCryst Pharmaceuticals Inc. The current rsi is 54.17. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
BioCryst Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartBioCryst Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioCryst Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biocryst price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
BioCryst Pharmaceuticals Inc Daily Stochastic Oscillator ChartBioCryst Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioCryst Pharmaceuticals Inc. The current cci is 77.62.

BioCryst Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartBioCryst Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioCryst Pharmaceuticals Inc. The current cmo is 7.25854575.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioCryst Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartBioCryst Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioCryst Pharmaceuticals Inc. The current willr is -45.55555556.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biocryst is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioCryst Pharmaceuticals Inc Daily Williams %R ChartBioCryst Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioCryst Pharmaceuticals Inc. The current atr is 0.33045899.

BioCryst Pharmaceuticals Inc Daily Average True Range (ATR) ChartBioCryst Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioCryst Pharmaceuticals Inc. The current obv is -48,686,794.

BioCryst Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartBioCryst Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioCryst Pharmaceuticals Inc. The current mfi is 58.77.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
BioCryst Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartBioCryst Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioCryst Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-06-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

BioCryst Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioCryst Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.174
Ma 20Greater thanMa 506.325
Ma 50Greater thanMa 1005.845
Ma 100Greater thanMa 2005.519
OpenGreater thanClose6.630
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biocryst with someone you think should read this too:
  • Are you bullish or bearish on Biocryst? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biocryst? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioCryst Pharmaceuticals Inc

I send you an email if I find something interesting about BioCryst Pharmaceuticals Inc.


Stay informed about BioCryst Pharmaceuticals Inc.

Receive notifications about BioCryst Pharmaceuticals Inc in your mailbox!